Clinical trial
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
NCT00174616 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00174616 |
|---|---|
| Title | CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision |
| Official title | Phase 2 Study of Weekly Oxaliplatin and Capecitabine (XELOX) in Combination With Preoperative Radiotherapy in Patients With MRI Defined Locally Advanced Rectal Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Neoplasms |
| Intervention type | Drug |
| Interventions | Oxaliplatin, capecitabine, radiotherapy |
| Enrollment | 87 |
| Start date | Jul 1, 2003 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 7, 2009 |
| Countries | Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: